These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Discovery of the First Examples of Threonine Tyrosine Kinase PROTAC Degraders. Lu J; Huang Y; Huang J; He R; Huang M; Lu X; Xu Y; Zhou F; Zhang Z; Ding K J Med Chem; 2022 Feb; 65(3):2313-2328. PubMed ID: 35084180 [TBL] [Abstract][Full Text] [Related]
7. Cellular Resistance Mechanisms to Targeted Protein Degradation Converge Toward Impairment of the Engaged Ubiquitin Transfer Pathway. Ottis P; Palladino C; Thienger P; Britschgi A; Heichinger C; Berrera M; Julien-Laferriere A; Roudnicky F; Kam-Thong T; Bischoff JR; Martoglio B; Pettazzoni P ACS Chem Biol; 2019 Oct; 14(10):2215-2223. PubMed ID: 31553577 [TBL] [Abstract][Full Text] [Related]
8. Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds. Chan KH; Zengerle M; Testa A; Ciulli A J Med Chem; 2018 Jan; 61(2):504-513. PubMed ID: 28595007 [TBL] [Abstract][Full Text] [Related]
11. Design, Synthesis, and Biological Evaluation of MEK PROTACs. Vollmer S; Cunoosamy D; Lv H; Feng H; Li X; Nan Z; Yang W; Perry MWD J Med Chem; 2020 Jan; 63(1):157-162. PubMed ID: 31804822 [TBL] [Abstract][Full Text] [Related]
12. Discovery of potent small molecule PROTACs targeting mutant EGFR. Zhao HY; Yang XY; Lei H; Xi XX; Lu SM; Zhang JJ; Xin M; Zhang SQ Eur J Med Chem; 2020 Dec; 208():112781. PubMed ID: 32883633 [TBL] [Abstract][Full Text] [Related]
13. Design and optimization of oestrogen receptor PROTACs based on 4-hydroxytamoxifen. Loren G; Espuny I; Llorente A; Donoghue C; Verdaguer X; Gomis RR; Riera A Eur J Med Chem; 2022 Dec; 243():114770. PubMed ID: 36148710 [TBL] [Abstract][Full Text] [Related]
14. Structural basis of PROTAC cooperative recognition for selective protein degradation. Gadd MS; Testa A; Lucas X; Chan KH; Chen W; Lamont DJ; Zengerle M; Ciulli A Nat Chem Biol; 2017 May; 13(5):514-521. PubMed ID: 28288108 [TBL] [Abstract][Full Text] [Related]
15. Bivalent Ligands for Protein Degradation in Drug Discovery. Scheepstra M; Hekking KFW; van Hijfte L; Folmer RHA Comput Struct Biotechnol J; 2019; 17():160-176. PubMed ID: 30788082 [TBL] [Abstract][Full Text] [Related]
16. VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives. Wang C; Zhang Y; Wang J; Xing D Eur J Med Chem; 2022 Jan; 227():113906. PubMed ID: 34656901 [TBL] [Abstract][Full Text] [Related]
17. Potent and Selective Mitogen-Activated Protein Kinase Kinase 1/2 (MEK1/2) Heterobifunctional Small-molecule Degraders. Hu J; Wei J; Yim H; Wang L; Xie L; Jin MS; Kabir M; Qin L; Chen X; Liu J; Jin J J Med Chem; 2020 Dec; 63(24):15883-15905. PubMed ID: 33284613 [TBL] [Abstract][Full Text] [Related]
18. Ternary Complex-Templated Dynamic Combinatorial Chemistry for the Selection and Identification of Homo-PROTACs. Diehl CJ; Salerno A; Ciulli A Angew Chem Int Ed Engl; 2024 Jun; 63(25):e202319456. PubMed ID: 38626385 [TBL] [Abstract][Full Text] [Related]
19. A "Click Chemistry Platform" for the Rapid Synthesis of Bispecific Molecules for Inducing Protein Degradation. Wurz RP; Dellamaggiore K; Dou H; Javier N; Lo MC; McCarter JD; Mohl D; Sastri C; Lipford JR; Cee VJ J Med Chem; 2018 Jan; 61(2):453-461. PubMed ID: 28378579 [TBL] [Abstract][Full Text] [Related]
20. Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity. Lv D; Pal P; Liu X; Jia Y; Thummuri D; Zhang P; Hu W; Pei J; Zhang Q; Zhou S; Khan S; Zhang X; Hua N; Yang Q; Arango S; Zhang W; Nayak D; Olsen SK; Weintraub ST; Hromas R; Konopleva M; Yuan Y; Zheng G; Zhou D Nat Commun; 2021 Nov; 12(1):6896. PubMed ID: 34824248 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]